Proteomic explorations of autism spectrum disorder.
Proteomics has not yet delivered a reliable autism blood test, so keep diagnostics rooted in behavior.
01Research in Context
What this study did
Szoko et al. (2017) read every proteomics paper on autism they could find. They wanted to see if blood or tissue protein patterns could flag autism or point to drug targets.
They only found narrative reports and tiny case-control studies. None used brain tissue. Most drew blood from fewer than 30 kids.
What they found
The review says the field is still a mess. Labs report different protein peaks. Sample sizes are small. Results rarely repeat.
Because studies use blood, not brain, the findings may say more about body inflammation than about autism itself.
How this fits with other research
Later blood tests look more hopeful, but still echo the same limits. Heald et al. (2020) reached 91 % specificity with a 34-metabolite toddler panel, yet sensitivity stayed at only 53 %. Zhu et al. (2022) tied gut amino-acid levels to symptom severity, but again used stool, not brain.
Older amino-acid papers fit the same pattern. Tirouvanziam et al. (2012) and Katz et al. (2003) both found odd plasma amino-acid profiles, but sample sizes were small and results conflict. These studies are the very ones Nicholas et al. flag as shaky.
No proteomics paper has overturned the review’s warning. The field still needs bigger samples, brain tissue, and replication before you can trust any blood test as a stand-alone autism screen.
Why it matters
For now, treat any “autism protein panel” sales pitch with caution. You can run blood chemistry for medical care, but don’t use it to diagnose or rule out autism. Keep watching the literature; once multi-site brain proteomics arrive, valid biomarkers may follow.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →If a family brings a “protein signature” lab report, praise their curiosity but steer assessment back to ADOS and caregiver interviews.
02At a glance
03Original abstract
Proteomics, the large-scale study of protein expression in cells and tissues, is a powerful tool to study the biology of clinical conditions and has provided significant insights in many experimental systems. Herein, we review the basics of proteomic methodology and discuss challenges in using proteomic approaches to study autism. Unlike other experimental approaches, such as genomic approaches, there have been few large-scale studies of proteins in tissues from persons with autism. Most of the proteomic studies on autism used blood or other peripheral tissues; few studies used brain tissue. Some studies found dysregulation of aspects of the immune system or of aspects of lipid metabolism, but no consistent findings were noted. Based on the challenges in using proteomics to study autism, we discuss considerations for future studies. Apart from the complex technical considerations implicit in any proteomic analysis, key nontechnical matters include attention to subject and specimen inclusion/exclusion criteria, having adequate sample size to ensure appropriate powering of the study, attention to the state of specimens prior to proteomic analysis, and the use of a replicate set of specimens, when possible. We conclude by discussing some potentially productive uses of proteomics, potentially coupled with other approaches, for future autism research including: (1) proteomic analysis of banked human brain specimens; (2) proteomic analysis of tissues from animal models of autism; and (3) proteomic analysis of induced pluripotent stem cells that are differentiated into various types of brain cells and neural organoids. Autism Res 2017, 10: 1460-1469. © 2017 International Society for Autism Research, Wiley Periodicals, Inc.
Autism research : official journal of the International Society for Autism Research, 2017 · doi:10.1002/aur.1803